InnoCon Medical, established in 2017 and headquartered in Aalborg, Denmark, is a medical device company specializing in neurostimulation technologies aimed at treating overactive bladder and fecal incontinence. The company's mission is to enhance the quality of life for individuals suffering from incontinence by providing innovative, non-invasive, and cost-effective therapeutic solutions.
Key Strategic Focus
InnoCon Medical's primary objective is to develop and commercialize the UCon neurostimulator, a device designed to deliver electrical stimulation to the dorsal genital nerve. This approach offers a less invasive alternative to traditional treatments, targeting patients who have not responded to conservative methods. The company is currently focused on conducting clinical investigations to gather the necessary data for regulatory approval and market entry in Europe.
Pipeline Development
The UCon neurostimulator is the flagship product in InnoCon Medical's pipeline. The device utilizes two types of electrodes—a Bar Electrode and a Patch Electrode—to deliver targeted neurostimulation. As of 2025, the company is conducting three feasibility studies to evaluate the efficacy and safety of the UCon device. Approval has been obtained for a feasibility study on the Bar Electrode, and a pivotal study with the Patch Electrode is forthcoming. These studies are critical steps toward obtaining the clinical data required for regulatory approval and subsequent market launch.
Technological Platform and Innovation
InnoCon Medical's innovation lies in its proprietary neurostimulation technology, which focuses on the electrical stimulation of the dorsal genital nerve to alleviate incontinence symptoms. The UCon device is designed for ease of use, featuring highly flexible electrode units that ensure stable and comfortable contact with the targeted nerve areas. This design minimizes patient discomfort and enhances treatment adherence. The company has secured multiple patents related to its neurostimulation systems, underscoring its commitment to technological advancement and intellectual property protection.
Leadership Team
The leadership team at InnoCon Medical comprises experienced professionals dedicated to advancing neurostimulation therapies:
- Torsten Fjeldgaard Hvalsøe: Co-inventor and key contributor to the development of the UCon device, with expertise in medical device innovation.
- Dianna Mærsk Knudsen: Co-inventor with a background in medical research and development, instrumental in the clinical aspects of product development.
- Jesper Nielsen: Co-inventor specializing in engineering and design, contributing to the technical development of the company's products.
Competitor Profile
InnoCon Medical operates in the competitive field of medical devices for incontinence treatment. Key competitors include:
- Inspire Medical Systems: Specializes in neurostimulation devices for sleep apnea, with a strong market presence and significant media coverage.
- Alpha Tau Medical: Develops innovative cancer therapies, with a focus on targeted radiation treatments.
- Neuronetics: Offers transcranial magnetic stimulation devices for depression treatment, showcasing expertise in non-invasive neurostimulation technologies.
These companies represent the broader landscape of neurostimulation and medical device firms, highlighting the competitive environment in which InnoCon Medical operates.
Strategic Collaborations and Partnerships
To enhance its clinical data management capabilities, InnoCon Medical has partnered with Greenlight Guru Clinical, adopting their electronic data capture (EDC) system. This collaboration has streamlined the company's clinical investigations, providing real-time data oversight and improving data completeness. The intuitive user experience of the EDC system has also facilitated better engagement with clinical sites, leading to more efficient study execution.
Operational Insights
InnoCon Medical's strategic focus on developing a non-invasive, user-friendly neurostimulation device positions it uniquely in the market. By addressing the limitations of existing treatments for incontinence, the company aims to capture a significant share of the market segment seeking alternatives to invasive procedures. The emphasis on patient comfort and ease of use serves as a distinct competitive advantage.
Strategic Opportunities and Future Directions
Looking ahead, InnoCon Medical plans to:
- Advance Clinical Trials: Complete ongoing feasibility and pivotal studies to gather robust clinical evidence supporting the UCon device's efficacy and safety.
- Regulatory Approvals: Pursue necessary regulatory approvals in Europe, paving the way for market entry and commercialization.
- Market Expansion: Explore opportunities for expanding into additional markets, including North America and Asia, to address the global need for innovative incontinence treatments.
- Product Development: Continue research and development efforts to enhance existing products and develop new solutions addressing related medical conditions.
By leveraging its technological innovations and strategic partnerships, InnoCon Medical is well-positioned to make significant contributions to the field of neurostimulation therapies for incontinence.
Contact Information
- Website: InnoCon Medical
- LinkedIn: InnoCon Medical LinkedIn
- Twitter: InnoCon Medical Twitter
- Facebook: InnoCon Medical Facebook
